SCHEMBL3852587

SCHEMBL3852587

COOC(=O)[C@@H](N)Cc1cn(Cc2cccc(C)c2)c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
ALDH1A1 P00352 6/20 0.48
LMNA P02545 5/20 0.48
MAPT P10636 4/20 0.48
NPSR1 Q6W5P4 3/20 0.48
ICMT O60725 3/20 0.47
RECQL P46063 1/20 0.45
CHRNB2 P17787 1/20 0.44
CHRNA7 P36544 1/20 0.44
CHRNA4 P43681 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
PLA2G2A P14555 1/20 0.42
POLB P06746 1/20 0.42
MEN1 O00255 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TACR1 P25103 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3854563 0.93 KMT2A (0.52) KMT2AALDH1A1LMNAMAPTNPSR1
SCHEMBL3855610 0.91 KMT2A (0.55) KMT2AALDH1A1LMNAMAPTNPSR1
SCHEMBL3853681 0.89 MAPT (0.52) KMT2AALDH1A1LMNAMAPTRECQL
SCHEMBL3858061 0.86 ICMT (0.53) KMT2AALDH1A1LMNAMAPTICMT
SCHEMBL3848663 0.83 CHRNB2 (0.57) KMT2AALDH1A1LMNAMAPTRECQL
SCHEMBL3848897 0.83 TP53 (0.51) KMT2AALDH1A1MAPTNPSR1RECQL
SCHEMBL3855899 0.82 CNR2 (0.53) KMT2AALDH1A1LMNAMAPTRECQL
SCHEMBL9584105 0.81 KMT2A (0.65) KMT2AALDH1A1LMNAMAPTRECQL
SCHEMBL3849471 0.81 KMT2A (0.55) KMT2AALDH1A1MAPTRECQLPOLB
SCHEMBL3849173 0.80 MAPT (0.55) KMT2AALDH1A1LMNAMAPTCHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576222-B2 N-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-1-(2-fluorobenzyl)-5-methoxy-2-methyltryptophan; for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, or Crohn's disease WYETH (US) 2009-08-18 US disclosed
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase WYETH (US) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase ADAM17, TPSAB1, ADAM10 KMT2A 1950/4885ALDH1A1 740/4885LMNA 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.